KPV

Lysine-Proline-Valine (alpha-MSH fragment)

KPV is a tiny fragment of alpha-MSH — three amino acids that kept the anti-inflammatory properties without the skin darkening or appetite changes. The mouse gut data is genuinely interesting: it enters intestinal cells through a specific transporter and dials down inflammatory signaling. The problem is that the gap between mouse colitis models and your actual gut is enormous. Community sentiment reflects that — more people are asking 'is this doing anything?' than saying it worked. Oral (enteric-coated) actually outperforms injections for gut issues, which is unusual for peptides.

Protocol

Dose: 500mcg oral (enteric-coated capsules) or 200-500mcg SubQ | Frequency: Twice daily for oral, once daily for SubQ | Cycle: 4-8 weeks continuous, then reassess based on symptoms | Route: Oral (enteric-coated, preferred for gut) or SubQ

Reconstitution: For SubQ: 1mL bacteriostatic water per 5mg vial. Oral capsules need enteric coating — plain oral gets destroyed by stomach acid.. Use our free reconstitution calculator for exact syringe units.

Effects

• Gut inflammation reduction (55%) — The primary use case. Mouse data is solid, human reports are mixed. Improvements reported within 10-14 days when they happen.
• IBD symptom relief (45%) — Ulcerative colitis and general IBD are the main community targets. Results vary wildly between people.
• Skin inflammation (35%) — Some people use it for eczema and psoriasis. Less data here than gut, but the mechanism is the same.
• General anti-inflammatory (30%) — Broad anti-inflammatory effect via NF-kB pathway inhibition. More subtle than the gut-specific benefits.

Side Effects

• Nausea (12%) — Kind of ironic for a gut peptide, but some people get nausea early on. It passes.
• Headache (7%) — Mild headache sometimes. No pattern to it — doesn't seem dose-related.
• Fatigue (5%) — Tired the first week. Your body's adjusting. Usually fine by week two.
• No response (30%) — Real talk: about a third of people feel nothing. The Reddit threads are full of 'is this even doing anything?' posts.

Evidence

Early research — Preclinical only — mouse colitis models show oral KPV reduces inflammation via the PepT1 transporter. No human clinical trials exist. Community adoption is significant but Reddit sentiment actually skews negative: worry and troubleshooting posts outnumber positive reports roughly 1.5 to 1. FDA PCAC meeting was scheduled for July 2026.

Approval status: Not approved. Preclinical only.

References

1. Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation Gastroenterology, 2008. PMID: 18061177
2. Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease Inflamm Bowel Dis, 2008. PMID: 18092346
3. Getting SJ et al. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides J Pharmacol Exp Ther, 2003. PMID: 12750433
4. Luger TA et al. alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs Ann Rheum Dis, 2007. PMID: 17934097
5. Cutuli M et al. Antimicrobial effects of alpha-MSH peptides J Leukoc Biol, 2000. PMID: 10670585

Storage

• Lyophilized: Refrigerate 2-8C or freeze -20C for long-term. Stable as dry powder for 12+ months.
• Reconstituted: Refrigerate at 2-8C. Use within 4 weeks. Do not freeze.
• Water: Bacteriostatic water for SubQ reconstitution. Oral capsules are pre-formulated.
• Needle: 30-31 gauge, 0.5 inch for SubQ injection

← Browse all peptides | Dose calculator →

These statements have not been evaluated by the FDA. This content is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any protocol.

vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify